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1  | INTRODUC TION
Ovarian cancer is a common malignant disease and is reported to be 
the fifth leading cause of cancer- related death in women.1 In Korea, 
it was reported to be the tenth most common cancer in women, and 
the 5- year survival rate of ovarian cancer was 64.1%, according to 
domestic statistics from the National Cancer Information Center for 
2010- 2014.2 The prognosis of this tumor is known to be relatively 
good if diagnosed in early stages;3,4 however, about 3/4 of ovarian 
cancer patients are diagnosed in advanced stages, and the survival 
rate is as low as 10%- 20% in these cases. Therefore, the early detec-
tion of ovarian cancer is important for improving patient prognosis.5
CA 125 is a widely used tumor marker for diagnosis and monitor-
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Objective: We evaluated the diagnostic performance of CA 125, HE4, and ROMA for 
ovarian cancer in Koreans and set optimal cutoffs.
Method: Serum levels of HE4 and CA 125 and the ROMA score were determined in 
762 patients with benign gynecological disease and 70 with ovarian cancer. Receiver 
operating characteristic curves were constructed to calculate the areas under the 
curve (AUC). CA 125, HE4, and ROMA exhibiting maximum Youden index were de-
termined, respectively, as the optimal cutoffs, and sensitivity and specificity were 
evaluated by applying those cutoffs.
Results: In benign diseases, CA 125 significantly increased in patients with uterine 
myoma, adenomyosis, endometrial pathology, or endometriosis, but HE4 only in-
creased in patients with adenomyosis. For the diagnosis of ovarian cancer, the com-
bination of CA 125, HE4, and age showed the highest AUC value of 0.892 in the 
premenopausal group, and ROMA demonstrated the best diagnostic performance, 
with an AUC of 0.935 in postmenopausal patients. When the optimal cutoff values 
for CA 125 and HE4 were applied, the sensitivities of CA 125, HE4, and ROMA in 
premenopausal women were all the same at 0.714, while the specificities were 0.841, 
0.974, and 0.972, respectively. In the postmenopausal group, the sensitivities of 
these markers were 0.857, 0.804, and 0.929, and the specificities were 0.836, 0.887, 
and 0.800, respectively.
Conclusion: Although all markers demonstrated good diagnostic performance, they 
varied depending on the pathologic types of benign diseases and ovarian cancer. For 
accurate diagnosis of ovarian cancer, CA 125, HE4, and ROMA should be used 
complementarily.
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of ovarian cancer.6 It also has a high false positive rate in benign 
gynecological diseases such as ovarian cysts and uterine myomas.7 
Therefore, CA 125 alone is not sufficient for screening and differen-
tial diagnosis of ovarian cancer.8 Given these circumstances, many 
studies have introduced human epididymis protein 4 (HE4) as a new 
tumor marker to help diagnose ovarian cancer.9-11 In 2010, the US 
FDA approved the Risk of Ovarian Malignancy Algorithm (ROMA) 
equation using both CA 125 and HE4 levels and patient menopausal 
state as a new biomarker for the diagnosis of ovarian cancer.12-14 
Since then, many studies have reported that the simultaneous test-
ing of HE4 and CA 125 with calculation of ROMA is valuable in the 
diagnosis of ovarian cancer.
In Korea, the HE4 test has been utilized as a new biomarker for 
ovarian cancers since 2014. Although many studies have been con-
ducted regarding the diagnostic performance of HE4, CA 125, and 
ROMA in different countries and races,12,15,16 there is little research 
on the utility of HE4 and ROMA in Korean women.17 Therefore, it is 
necessary to investigate the clinical utility of HE4 and CA 125 and to 
identify the optimal ROMA cutoff for the diagnosis of ovarian cancer 
in Koreans.
In this study, we evaluated the diagnostic performance of CA 
125, HE4, and ROMA for ovarian cancer in Koreans and set the opti-
mal cutoff for each tumor marker.
2  | MATERIAL S AND METHODS
2.1 | Study subjects
The HE4 assay was requested for a total of 845 patients who vis-
ited the Department of Obstetrics and Gynecology, National Health 
Insurance Service Ilsan Hospital, from March 2015 to August 2017 
with suspected gynecological disease. Of these patients, we ex-
cluded 13 patients including four cases not tested for CA 125, six 
patients with malignant disease other than ovarian cancer, and three 
patients who had follow- up HE4 blood tests. Finally, medical re-
cords of 832 patients were reviewed retrospectively. Patients’ ages; 
CA 125 and HE4 levels; menopausal state; final diagnosis based on 
clinical, histologic, and radiologic findings; and the International 
Federation of Gynecology and Obstetrics (FIGO) stages of ovarian 
cancer were recorded. This study was approved by the Institutional 
Review Board of National Health Insurance Service Ilsan Hospital 
(IRB no. 2017- 01- 038).
2.2 | CA 125 and HE4 assays
CA 125 and HE4 tests were performed with a Cobas E 602 immuno-
assay analyzer using Elecsys CA 125 II and Elecsys HE4 test reagents 
(Roche Diagnostics GmbH, Mannheim, Germany) according to the 
manufacturer’s instructions. Both assays utilize the electrochemi-
luminescence immunoassay (ECLIA) principle. CA 125 levels were 
measured by the Department of Laboratory Medicine at National 
Health Insurance Ilsan Hospital, and HE4 concentrations were 
determined by the Green Cross Reference Laboratory (Yongin- si, 
Gyeonggi- do, Republic of Korea). The manufacturer suggests a CA 
125 cutoff of >35 U/mL and provides the reference limit for each age 
group in HE4. However, the cutoff of HE4 for diagnosing cancer was 
not presented; therefore, we used the default cutoff of HE4 set by 
the Green Cross Reference Laboratory (>92.1 pmol/L for premeno-
pausal women and >121.1 pmol/L for postmenopausal women).
2.3 | Calculation of ROMA value
Using the concentrations of CA 125 and HE4, we calculated ROMA 
according to the mathematical equations presented below.





The cutoff value of the ROMA proposed by the manufacturer was 
≥11.4%	 in	 premenopausal	 women	 and	 ≥29.9%	 in	 postmenopausal	
women.
2.4 | Statistical analyses
All statistical analyses were performed by Analyse- it for Microsoft 
Excel Method Evaluation Edition version 3.76.1 (Analyse- it Software, 
Ltd., Leeds, UK) and IBM SPSS Statistics 23 (IBM Corp., Armonk, 
NY, US). For continuous variables, the Mann- Whitney U test and 
Kruskal- Wallis test were used for comparisons between two groups 
and among three or more groups, respectively. The Steel multiple 
comparison test was performed to compare the control with several 
other groups to compensate for alpha error. The Chi- square test was 
used to compare the categorical variables between the study groups. 
To analyze the diagnostic performance of each tumor marker and 
the ROMA value in ovarian cancer, receiver operating characteristic 
(ROC) curves were constructed, and the area under the curve (AUC) 
of each marker was calculated according to the method proposed by 
DeLong et al18 From the results of ROC curve analyses, the CA 125, 
HE4, and ROMA with maximal values of Youden index were deter-
mined, respectively, as the optimal cutoff values. Sensitivity, speci-
ficity, and positive and negative predictive values (PPV and NPV) 
were evaluated when diagnosing ovarian cancer by applying default 
and optimal cutoff values. Diagnostic accuracy was calculated as 
(sensitivity	+	specificity)/2.	 Multivariate	 analysis	 was	 performed	
with binary logistic regression with the diagnosis of ovarian cancer 
as a binary- dependent variable and patient age, menopausal state, 
and each test’s values as independent variables to identify variables 
significantly correlated with diagnosis of ovarian cancer. The esti-
mated probabilities calculated from the combination of independent 
variables were used in ROC curve analyses to evaluate the diagnos-
tic performance of the combination of variables. For all statistical 
analyses, a P-	value≤0.05	was	considered	significant.
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3  | RESULTS
3.1 | Characteristics of study subjects
Of the 832 patients, 762 and 70 were diagnosed with benign gy-
necological diseases and ovarian cancer, respectively. The clinical 
characteristics of each group are shown in Table 1. There were sig-
nificant differences in age, CA 125 and HE4 levels, and proportion of 
menopausal patients between the two groups. In the benign disease 
group, 284 (37.3%) had ovarian cysts/tumors, 217 (28.5%) had uter-
ine leiomyomas, 80 (10.5%) had adenomyosis, 77 (10.1%) had en-
dometrial pathology, and 69 (9.1%) had endometriosis of the ovary. 
In patients with ovarian cancer, endometrioid adenocarcinoma was 
seen in 12 patients (17.1%), followed by 11 (15.7%) with serous ad-
enocarcinoma, 11 (15.7%) with adenocarcinoma, 4 (5.7%) with muci-
nous adenocarcinoma, and 4 (5.7%) with clear cell adenocarcinoma. 
Regarding the FIGO stages of cancer patients, 19 (27.1%) cases were 
TABLE  1 Characteristics of study subjects
Parameter Benign disease (N = 762) Ovarian cancer (N = 70) P- value
Age (y)a 45.0 (36.0- 51.0) 64.0 (50.9- 77.0) <0.0001
CA 125 level (U/mL)a 17.1 (12.0- 35.5) 90.5 (30.9- 416.6) <0.0001
HE4 level (pmol/L)a 47.2 (40.9- 55.3) 163.9 (88.1- 473.9) <0.0001
No. of menopausal subjects, N (%) 195 (25.6%) 56 (80.0%) <0.0001
Diagnosis, N (%) Ovarian cyst(s)/tumor(s), 284 (37.3%) Ovarian cancer, 70 (100.0%) - 
Uterine leiomyoma, 217 (28.5%)
Adenomyosis, 80 (10.5%)
Endometrial pathology, 77 (10.1%)
Endometriosis of ovary, 69 (9.1%)
Pelvic inflammatory disease, 11 (1.4%)
Polycystic ovarian disease, 4 (0.5%)
Other benign conditions, 20 (2.6%)b
Pathologic finding, N (%) Leiomyoma, 164 (21.5%) Surface epithelial- stromal tumors - 
Adenomyosis, 65 (8.5%) Endometrioid adenocarcinoma, 12 
(17.1%)
Endometrial polyp/hyperplasia, 63 
(8.3%)
Serous adenocarcinoma, 11 (15.7%)
Endometriosis/endometriotic cyst, 58 
(7.6%)
Adenocarcinoma, 11 (15.7%)
Mature cystic teratoma, 45 (5.9%) Mucinous adenocarcinoma, 4 (5.7%)
Mucinous cystadenoma, 28 (3.7%) Clear cell adenocarcinoma, 4 (5.7%)
Serous cystadenoma, 23 (3.0%) Carcinosarcoma, 3 (4.3%)
Other benign cyst(s)/tumor(s), 43 
(5.6%)
Sex cord- stromal tumors
Inflammation, 5 (0.7%) Granulosa cell tumor, 3 (4.3%)
Other benign conditions, 5 (0.7%) Germ cell tumors
No pathologic diagnosis, 9 (1.2%) Immature teratoma, 3 (4.3%)
Biopsy not done, 254 (33.3%) Malignant, not otherwise specified
Metastatic adenocarcinoma, 3 (4.3%)
Diffuse large B cell lymphoma, 1 (1.4%)
Biopsy/surgery not done, 15 (21.4%)




FIGO, the International Federation of Gynecology and Obstetrics.
aData are shown as median (1st to 3rd quartiles).
bCases of dysfunctional uterine bleeding (N = 4), non- gynecological problems (N = 4), uterovaginal prolapse (N = 4), vulvar mass (N = 2), amenorrhea, 
dysmenorrhea, torsion of ovary, premature ovarian failure, invasive hydatidiform mole, and bacterial vaginosis.
4 of 8  |     KIM et al.
in stage I, 2 (2.9%) were in stage II, 31 (44.3%) were in stage III, and 
18 (25.7%) were in stage IV.
3.2 | Tumor marker levels in benign diseases and 
ovarian cancer
The levels of CA 125 and HE4 in benign gynecological diseases are 
presented in Table 2. The level of CA 125 was significantly higher in 
uterine myoma, adenomyosis, endometrial pathology, and endome-
triosis of the ovary than in the ovarian cyst/tumor group. Meanwhile, 
HE4 concentration was statistically higher only in the adenomyosis 
group compared to the ovarian cyst/tumor group.
The levels of CA 125 and HE4 according to pathologic findings 
and FIGO stage of ovarian cancer are shown in Table 3. Within the 
surface epithelial- stromal tumor group, the level of CA 125 was not 
statistically different between the endometrioid adenocarcinoma 
and other subgroups of surface epithelial- stromal tumor. However, 
the level of HE4 was significantly lower (P = 0.0249) in clear cell 
adenocarcinoma compared to endometrioid adenocarcinoma as a 
control group. In the comparison between surface epithelial- stromal 
tumor and other pathologic types, the level of CA 125 was statisti-
cally lower in the germ cell tumors (P = 0.0270); however, the level of 
HE4 showed no significant difference. In addition, the levels of both 
tumor markers increased significantly as the FIGO stage progressed.
3.3 | Diagnostic performance of each tumor marker 
for ovarian cancer
To investigate the independent variable significantly related to the 
diagnosis of ovarian cancer, multivariate logistic regression analysis 
was performed. For premenopausal patients, patient age and the 
level of CA 125 were significantly associated with ovarian cancer. 
For postmenopausal patients, both CA 125 and HE4 levels were 
related to diagnosis of ovarian cancer. When evaluating all patients 
regardless of menopausal state, the levels of CA 125 and HE4 and 
menopausal state were significant independent variables for the di-
agnosis of ovarian cancer (Table 4).
The diagnostic performance of each tumor marker, ROMA val-
ues, and the combinations of these tumor markers are summarized in 
Table 5. In the premenopausal patient group, the combination of CA 
125	+	HE4	+	age	showed	 the	highest	AUC	value	of	0.892;	however,	
it was not statistically different from that of CA 125 (0.831). In the 
postmenopausal patient group, the ROMA value showed the highest 
AUC value of 0.935, and it was significantly different from that of CA 
125 (0.889, P = 0.0231), but not different from that of HE4 (0.882) or 
CA	125	+	HE4	combination	(0.927).	In	all	patients	regardless	of	meno-
pausal state, the AUC values of HE4, and the AUCs for the combinations 
of	CA	125	+	HE4,	CA	125	+	HE4	+	age,	CA	125	+	HE4	+	menopausal	
state,	and	CA	125	+	HE4	+	age	+	menopause	state	were	0.896,	0.909,	
0.892, 0.931, and 0.923, respectively, and these values were signifi-
cantly higher than that of CA 125 alone (0.811).
The sensitivity, specificity, PPV, and NPV from the ROC curve 
analysis using the default cutoff and the optimal cutoff of each 
tumor marker are presented in Table 6. In the premenopausal pa-
tient group, when the optimal cutoff (>71.7 U/mL) rather than the 
default cutoff (>35 U/mL) was applied, the sensitivity was the same, 
at 0.714; however, the specificity increased from 0.695 to 0.841 
for CA 125. The diagnostic accuracy also increased from 0.705 to 
0.778. For HE4, the specificity decreased from 0.986 to 0.974; how-
ever, the sensitivity increased from 0.571 to 0.714 when the opti-
mal cutoff (>83.0 pmol/L) was used rather than the default cutoff 
(>92.1 pmol/L). The diagnostic accuracy of HE4 also increased from 
0.779 to 0.844. Regarding ROMA values, the sensitivity was the 
same, at 0.714, but the specificity improved from 0.875 to 0.972.
In the postmenopausal patient group, the sensitivity of CA 125 
was enhanced from 0.714 to 0.857, but the specificity decreased 
Benign diseases CA 125 (U/mL) P- valuea HE4 (pmol/L) P- valuea
Ovarian cyst/tumor 
(N = 284)
14.3 (10.2- 22.2) - 46.0 (39.7- 55.0) - 
Uterine myoma 
(N = 217)
16.7 (12.1- 30.2) 0.0017 47.6 (42.7- 53.6) 0.7021
Adenomyosis (N = 80) 91.2 (38.8- 151.8) <0.0001 53.1 (45.7- 61.2) 0.0004
Endometrial 
pathology (N = 77)
16.4 (13.6- 26.9) 0.0116 48.9 (43.4- 60.5) 0.0792
Endometriosis of 
ovary (N = 69)
42.0 (24.8- 86.9) <0.0001 43.2 (38.2- 49.2) 0.1644
Pelvic inflammatory 
diseases (N = 11)
15.3 (10.4- 24.4) 1.0000 50.9 (35.2- 63.6) 1.0000
Polycystic ovarian 
disease (N = 4)
12.4 (11.2- 18.8) 1.0000 34.4 (30.0- 39.9) 0.0773
Others (N = 20) 12.6 (7.7- 25.3) 0.9993 46.0 (39.2- 53.3) 1.0000
Data are shown as median (1st to 3rd quartiles).
aP- value was calculated using the Steel multiple comparison with the ovarian cyst/tumor group as a 
control.
Bold values imply statistically significant results.
TABLE  2 CA 125 and HE4 levels 
according to benign disease
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from 0.903 to 0.836 with the optimal cutoff (>22.5 U/mL). 
Furthermore, the diagnostic accuracy improved to 0.847 from 0.809. 
For HE4, despite the decrease in specificity from 0.969 to 0.887, the 
sensitivity increased from 0.571 to 0.804 when the optimal cutoff 
(>85.5 pmol/L) was used. Therefore, the diagnostic accuracy im-
proved from 0.770 to 0.846. The sensitivity of ROMA was enhanced 
from 0.696 to 0.929, while the specificity was reduced from 0.913 to 
0.800 when the optimal cutoff was applied. Overall, the diagnostic 
accuracy increased from 0.805 to 0.865.
In all subjects regardless of menopausal state, the sensitivity of 
CA 125 improved from 0.714 to 0.814, but the specificity decreased 
from 0.748 to 0.665 when using the optimal cutoff of >26.6 U/mL. 
As a result, the diagnostic accuracy changed from 0.731 to 0.740. 
The sensitivity, specificity, and diagnostic accuracy of HE4 were 
0.800, 0.938, and 0.869, respectively, and HE4 showed a higher 
specificity and diagnostic accuracy than CA 125 when the optimal 
cutoff for HE4 (>79.6 pmol/L) was used.
4  | DISCUSSION
In this study, we analyzed the diagnostic performance of CA 125, 
HE4, and the combination of these two markers in the differential 
diagnosis of benign gynecological diseases and ovarian cancer in 
Korean patients. In addition, we tried to derive the optimal cut-
off suitable for a Korean population. A previous domestic study 
set the 95th percentile of CA 125, HE4, and ROMA from 1,809 
healthy people as the normal cutoff, and then these cutoffs were 
applied to differentiate 140 patients with ovarian cancer and 123 
with benign gynecological diseases. In the same study, the sensi-
tivity and specificity for CA 125 were 0.563 and 0.735 in patients 
less than 50 years of age and 0.859 and 0.762 in patients 50 years 
of age or older, respectively. The sensitivity and specificity of HE4 
were 0.359 and 0.951, respectively, in patients under the age of 
50 and 0.718 and 0.952 in subjects 50 years or older. In addition, 
the sensitivity and specificity of ROMA were 0.391 and 0.961, 
respectively, in premenopausal women and 0.845 and 0.800 in 
postmenopausal patients.17 Although the specificity in a certain 
group was high, the sensitivity was lower than 0.4; therefore, this 
makes it difficult to apply normal cutoff values in actual clinical 
situations. In contrast, we calculated the optimal cutoff values 
from gynecological diseases and ovarian cancer patients and ap-
plied these optimal cutoff values to diagnose ovarian cancer. As 
a result, the sensitivity increased to higher than 0.7 in premeno-
pausal patients and higher than 0.8 in postmenopausal women 
(Table 6).
TABLE  3 CA 125 and HE4 levels according to pathologic classification and FIGO stage of ovarian cancer
Classification CA 125 (U/mL) P- valuea HE4 (pmol/L) P- valuea
Pathology
Surface epithelial- stromal tumor 
(N = 45)
94.0 (38.9- 442.9) - 198.5 (83.2- 421.5) - 
Endometrioid adenocarcinoma 
(N = 12)
90.5 (49.3- 859.7) - 179.4 (83.9- 345.3) - 
Serous adenocarcinoma (N = 11) 126.3 (59.2- 592.6) 0.9999 317.7 (107.8- 1379.0) 0.8450
Adenocarcinoma (N = 11) 415.2 (250.5- 1167.0) 0.9370 225.0 (147.8- 1243.6) 0.7293
Mucinous adenocarcinoma (N = 4) 72.2 (29.5- 201.3) 0.8190 121.6 (57.5- 186.7) 0.7613
Clear cell adenocarcinoma (N = 4) 31.0 (21.0- 62.3) 0.7125 37.8 (35.3- 47.0) 0.0249
Carcinosarcoma (N = 3) 28.1 (13.9- 46.7) 0.7782 212.8 (126.8- 350.9) 1.0000
Sex cord- stromal tumor (N = 3) 25.4 (13.8- 42.0) 0.1318 95.1 (89.3- 171.4) 0.8733
Germ cell tumor (N = 3) 9.1 (7.2- 16.7) 0.0270 103.9 (97.3- 109.4) 0.8046
Malignant, not otherwise specified 
(N = 4)
93.4 (51.9- 170.2) 0.9903 95.8 (68.5- 687.0) 0.9568
Biopsy/surgery not done (N = 15) 270.4 (39.6- 1404.7) 0.9083 165.0 (88.0- 754.8) 0.9918
FIGO stage
I (N = 19) 28.1 (17.1- 54.9) - 84.6 (45.6- 108.1) - 
II (N = 2) 72.2 (50.4- 94.0) 0.2358 127.0 (41.2- 212.8) 0.9401
III (N = 31) 237.9 (53.9- 429.3) 0.0008 213.5 (105.0- 933.0) <0.0001
IV (N = 18) 388.9 (79.3- 1459.9) 0.0002 285.9 (99.7- 620.6) 0.0004
FIGO, the International Federation of Gynecology and Obstetrics.
Data are shown as median (1st to 3rd quartiles).
aP- value was calculated using the Steel multiple comparison with the surface epithelial- stromal tumor group as the control when comparing groups accord-
ing to the pathologic classification, and the endometrioid adenocarcinoma group was used as a control for comparing groups belonging to surface epithelial- 
stromal tumors. In addition, the stage I group was used as a control to compare CA 125 and HE4 levels according to FIGO stage of ovarian cancer.
Bold values imply statistically significant results.
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Meanwhile, we analyzed the levels of CA 125 and HE4 in various 
benign gynecological diseases. The level of CA 125 was significantly 
higher in uterine myomas, adenomyosis, endometrial pathologies, 
and endometriosis of the ovary than in the ovarian cyst/tumor group. 
On the other hand, the level of HE4 was statistically high only in the 
adenomyosis group. In our previous study, Park et al19,20 also re-
ported that the levels of CA 125 and HE4 increased in various benign 
gynecological diseases, especially in adenomyosis. The increase in CA 
125 and HE4 concentrations differed according to disease, and an 
increase in CA 125 was more frequent than an increase in HE4 in 
benign conditions, as our previous and current studies showed.19,20 
Therefore, it is considered that the specificity of HE4 is higher than 
that of CA 125. Furthermore, the degrees of increase in the levels 
of these tumor markers also varied according to the pathologic type 
of ovarian cancer. In this study, the level of CA 125 was low in germ 
cell tumor, whereas the level of HE4 was low in clear cell adenocar-
cinoma. Fujiwara et al differentiated low- grade serous/endometrioid 
carcinoma and every grade of clear cell, mucinous, and transitional 
carcinoma as type I ovarian cancer, while high- grade serous/endo-
metrioid carcinoma and malignant mixed mesodermal tumor were 
classified as type II ovarian cancer. In their study, the AUCs of CA 125 
for type I and type II cancer were 0.76 and 0.92, respectively, which 
were different from each other, and those of HE4 were 0.82 and 0.95. 
These results also demonstrate that the diagnostic performance of 
tumor markers differed according to the pathologic type of ovarian 
cancer.16 As CA 125 and HE4 levels vary in benign gynecological dis-
eases and pathologic types of ovarian cancers, it is desirable to use 
both tumor markers complementarily for diagnosing ovarian cancer.
In a meta- analysis of 28 studies, Wang et al reported that the 
sensitivity of HE4 for diagnosing ovarian cancer was 0.763, which 
was slightly lower than that of CA 125 (0.792); however, the spec-
ificity of HE4 was 0.936 and was significantly higher than that 
of CA 125 (0.821). In addition, they reported the sensitivity and 
specificity of ROMA as 0.853 and 0.824, respectively.21 Similar to 
the meta- analysis, the sensitivity and the specificity of CA 125 in 
our study were 0.857 and 0.836, respectively, and the sensitivity 
TABLE  4 Multivariate analysis of patient age and CA 125 and 
HE4 levels for the diagnosis of ovarian cancer
Group Variables Odds ratio (95% CI) P- value
Premenopause Age (y) 1.166 (1.011- 1.344) 0.0352
Case N = 14 CA 125 (U/mL) 1.005 (1.001- 1.010) 0.0142
Control 
N = 567
HE4 (pmol/L) 1.005 (0.999- 1.010) 0.0761
Postmenopause Age (y) 1.014 (0.982- 1.047) 0.3946
Case N = 56 CA 125 (U/mL) 1.006 (1.001- 1.011) 0.0227
Control N = 195 HE4 (pmol/L) 1.007 (1.000- 1.013) 0.0366
Total Age (y) 1.027 (0.998- 1.057) 0.0728
Case N = 70 CA 125 (U/mL) 1.006 (1.003- 1.009) 0.0004
Control N = 762 HE4 (pmol/L) 1.005 (1.002- 1.009) 0.0046
Menopause 7.220 (2.527- 20.630) 0.0002
CI, confidence interval.
Bold values imply statistically significant results.
Group Biomarker AUC (95% CI) P- valuea
Premenopause CA 125 (U/mL) 0.831 (0.711- 0.951) - 
Case N = 14 HE4 (pmol/L) 0.820 (0.656- 0.984) 0.8802
Control N = 567 ROMA (premenopause) 0.824 (0.664- 0.983) 0.9152
CA	125	+	HE4 0.847 (0.724- 0.970) 0.3902
CA	125	+	HE4	+	age 0.892 (0.805- 0.978) 0.1866
Postmenopause CA 125 (U/mL) 0.889 (0.836- 0.942) - 
Case N = 56 HE4 (pmol/L) 0.882 (0.821- 0.943) 0.8582
Control N = 195 ROMA (postmenopause) 0.935 (0.902- 0.969) 0.0231
CA	125	+	HE4 0.927 (0.887- 0.967) 0.1674
CA	125	+	HE4	+	age 0.878 (0.818- 0.939) 0.6852
Total CA 125 (U/mL) 0.811 (0.753- 0.869) - 
Case N = 70 HE4 (pmol/L) 0.896 (0.842- 0.951) 0.0191
Control N = 762 CA	125	+	HE4 0.909 (0.866- 0.952) 0.0008
CA	125	+	HE4	+	age 0.892 (0.845- 0.940) 0.0008
CA	125	+	HE4	+	menopause	
state
0.931 (0.894- 0.969) <0.0001
CA	125	+	HE4	+	age	+	men-
opause state
0.923 (0.890- 0.956) <0.0001
AUC, area under the receiver operating characteristics curve; CI, confidence interval; ROMA, Risk of 
Ovarian Malignancy Algorithm.
aAgainst AUC value of CA 125.
Bold values imply statistically significant results.
TABLE  5 Area under the receiver 
operating characteristics curve for the 
diagnosis of ovarian cancer
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and the specificity of HE4 were 0.804 and 0.887 when optimal 
cutoffs were applied to the postmenopausal patients. Similar to 
the meta- analysis described above, the sensitivity and the speci-
ficity of ROMA were 0.929 and 0.800, respectively, showing bet-
ter sensitivity than that of CA 125 and HE4 but lower specificity. 
Direct comparison of sensitivity and specificity among studies is 
difficult because of the differences in the types of benign gyneco-
logical diseases used as control groups, the stages and pathologic 
types of ovarian cancer patients, and the cutoff for diagnosing 
ovarian cancer. However, HE4 would have higher specificity but 
lower sensitivity than CA 125 based on the results of this and pre-
vious studies. Therefore, complementary combinations of the two 
tumor markers and ROMA would contribute to improving ovarian 
cancer diagnostic performance.
The aim of this study was to evaluate the diagnostic perfor-
mance of CA 125, HE4, and ROMA in Korean patients with benign 
gynecological diseases and ovarian cancer and to search for the 
ideal combination of CA 125 and HE4 to perform better than con-
ventional ROMA. However, only 70 ovarian cancer patients were 
included in our study, and little numbers of cases according to the 
pathologic classifications had to be compared as shown in Table 3. 
Furthermore, only 14 of them were premenopausal. Therefore, de-
riving an optimal combination statistically superior to ROMA was 
difficult due to the small number of cases. In this study, the AUC 
of	the	combination	of	CA	125	+	HE4	in	the	premenopausal	patient	
group was 0.847, which was higher than the AUC of ROMA (0.824), 
but the difference was not statistically significant (P = 0.6440). In 
the postmenopausal patient group, the AUC of ROMA was 0.935, 
which	 was	 higher	 than	 the	 AUC	 of	 CA	 125	+	HE4	 combination	
(0.927), but the difference was not significant (P = 0.2851). In 
 future studies, observing a large number of ovarian cancer patients 
could allow derivation of an optimal combination of CA 125 and 
HE4 that could be helpful for the diagnosis of ovarian cancer in 
Korean women. Furthermore, more researches should be done to 
confirm the better diagnostic performance of CA125, HE4, and 
ROMA when optimal cutoffs are applied.
In conclusion, this study evaluated the diagnostic performance 
of CA 125, HE4, and ROMA for ovarian cancer in Korean patients, 
and these markers demonstrated good diagnostic performance. 
The diagnostic performance of each marker varied depending on 
the type of benign gynecological disease and pathologic type of 
ovarian cancer. Therefore, CA 125, HE4, and ROMA should be used 
as complementary tests to improve the diagnosis of ovarian cancer.
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